Torben Redmer
Overview
Explore the profile of Torben Redmer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
445
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sternberg C, Raigel M, Limberger T, Trachtova K, Schlederer M, Lindner D, et al.
Mol Cancer
. 2024 Nov;
23(1):245.
PMID: 39482716
Background: Prostate cancer ranks as the second most frequently diagnosed cancer in men worldwide. Recent research highlights the crucial roles IL6ST-mediated signaling pathways play in the development and progression of...
2.
Soler-Saez I, Karz A, Hidalgo M, Gomez-Cabanes B, Lopez-Cerdan A, Catala-Senent J, et al.
J Invest Dermatol
. 2024 Sep;
PMID: 39326662
Melanoma represents a critical clinical challenge owing to its unfavorable outcomes. This type of skin cancer exhibits unique adaptability to the brain microenvironment, but its underlying molecular mechanisms are poorly...
3.
Redmer T, Raigel M, Sternberg C, Ziegler R, Probst C, Lindner D, et al.
Mol Cancer
. 2024 May;
23(1):114.
PMID: 38811984
Background: Prostate cancer develops through malignant transformation of the prostate epithelium in a stepwise, mutation-driven process. Although activator protein-1 transcription factors such as JUN have been implicated as potential oncogenic...
4.
Redmer T, Schumann E, Peters K, Weidemeier M, Nowak S, Schroeder H, et al.
Acta Neuropathol
. 2024 Mar;
147(1):63.
PMID: 38536477
No abstract available.
5.
Redmer T, Schumann E, Peters K, Weidemeier M, Nowak S, Schroeder H, et al.
Acta Neuropathol
. 2024 Feb;
147(1):44.
PMID: 38386085
The development of brain metastases hallmarks disease progression in 20-40% of melanoma patients and is a serious obstacle to therapy. Understanding the processes involved in the development and maintenance of...
6.
Radke J, Schumann E, Onken J, Koll R, Acker G, Bodnar B, et al.
Nat Commun
. 2022 Nov;
13(1):7304.
PMID: 36435874
Melanoma brain metastases (MBM) variably respond to therapeutic interventions; thus determining patient's prognosis. However, the mechanisms that govern therapy response are poorly understood. Here, we use a multi-OMICS approach and...
7.
Kumbrink J, Bohlmann L, Mamlouk S, Redmer T, Peilstocker D, Li P, et al.
Cancers (Basel)
. 2022 Jul;
14(15).
PMID: 35892888
Most metastatic colorectal cancer (mCRC) patients succumb to refractory disease due to secondary chemotherapy resistance. To elucidate the molecular changes associated with secondary resistance, we recruited 64 patients with mCRC...
8.
Strohmayer C, Klang A, Kummer S, Walter I, Jindra C, Weissenbacher-Lang C, et al.
Pathogens
. 2022 Feb;
11(2).
PMID: 35215208
Squamous cell carcinoma of the head and neck (HNSCC) is a common malignant tumor in humans and animals. In humans, papillomavirus (PV)-induced HNSCCs have a better prognosis than papillomavirus-unrelated HNSCCs....
9.
Vidal A, Redmer T
Int J Mol Sci
. 2022 Feb;
23(3).
PMID: 35163127
Clonal evolution and cellular plasticity are the genetic and non-genetic driving forces of tumor heterogeneity, which in turn determine tumor cell responses towards therapeutic drugs. Several lines of evidence suggest...
10.
Vidal A, Redmer T
Cancers (Basel)
. 2020 Sep;
12(9).
PMID: 32878000
The evolution of melanoma, the most aggressive type of skin cancer, is triggered by driver mutations that are acquired in the coding regions of particularly BRAF (rat fibrosarcoma serine/threonine kinase,...